Skip to content

Released Mar 6, 2023, after the close

10-K filed Mar 6, 2023, 65 days after period end · 0000950170-23-006242

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$122.23Mderived−2.3% vs Q4 2021+7.2% vs Q3 2022
Net Income-$7.06MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$89,176,000−2.9%
Operating Incomederived-$11,044,000N/M
Operating Cash Flowderived$2,348,000−80.1%
Free Cash Flowderived-$2,857,000N/M
Margins · derived
Gross margin73.0%−0.5 pt vs Q4 2021
Operating margin-9.0%−1.6 pt vs Q4 2021
Net margin-5.8%+20.5 pt vs Q4 2021

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019
Revenue$122.23M$125.06M$117.62M$121.49M
Net Income-$7.06M-$32.81M-$9.38M$11.69M
EPS Diluted———$0.60

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR